Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: you have + keyword you + search  Related to the article below (Last Update: 5/13/2008)


dBTechno
Posted by: Rob Hof on May 12
BusinessWeek -
What you notice immediately when searching on something, whether it?s in the form of a question or the usual keyword combinations, is that Powerset?s engine ...
Powerset Unveils Test Version of Google-killer ABC News
Powerset Launches Showcase For User Search Experience Washington Post
Powerset shows semantic search solution ZDNet Blogs
TechNewsWorld - RedOrbit
all 141 news articles »  GOOG - MSFT

bit-tech.net
Image-based search with TinEye
bit-tech.net, UK - 33 minutes ago
Wouldn't it be handy if you could just upload the closest equivalent image you have and let the power of the web do its magic thing? ...
Relevancy is What Matters in SEM
Promotion World (press release), CA - May 12, 2008
Keywords are just the tip of the search query iceberg: Advertise the keyword ?bicycle? on broad match and you could very well serve for searches on the ...
SEO and Meta Tags
Promotion World (press release), CA -
So, with present algorithms which are really smart and intelligent include only those relevant keywords you want to target and make sure that these are ...
Making the most of being a certified disadvantaged firm
Los Angeles Times, CA - May 12, 2008
Answer: There are professionals who do nothing but "optimize" websites for prominent search engine placement. If you can't afford one, here are some tips ...
SherpaBlog: 5 Ways to Improve Blog Results Today: How to Engage ...
MarketingSherpa.com (subscription), RI - May 11, 2008
While it?s fine to see how many visitors you get, the most useful report is actually the keyword analysis report. There, you?ll find a list of the terms ...
Good Old-Fashioned Link Building
ClickZ News, NY - May 11, 2008
You search for potential linking partners, approach them and ask for a link (and often you provide one in return). I refer to this approach as a "direct" ...

R744.com
? R744.com has evolved...
R744.com, Belgium - 33 minutes ago
Members section: After your FREE registration as an R744.com Member, you have full access to all additional features offered on the website, ...
Search Engine News, An In-Depth Look At Google's Tools & The ...
Search Engine Land, CT - May 9, 2008
This week, there was an update of the Keyword Tool. "You may have noticed that we made a change the traffic estimates data in the Keyword Tool. ...GOOG
SmartFinds Internet Marketing Improves Web Site Results for Top ...
PR Web (press release), WA -
You can learn more about SmartFinds at SmartfindsMarketing.com. Contact: Doug Menzer, PO Box 370, Bloomfield Hills, MI 48303, (866) 501-5758.PINK:IMIZ
Source: Google News

[CITATION] Inc
C Technology

Statistical analysis of cointegration vectors
S Johansen - Journal of Economic Dynamics and Control, 1988 - ideas.repec.org
... experience problems downloading a file, check if you have the proper ... the access to
this document is restricted, you may want ... y:1988:i:2-3:p:231-254 Keywords: ...

Measuring the efficiency of decision making units -
A Charnes, WW Cooper, E Rhodes - European Journal of Operational Research, 1978 - ideas.repec.org
... experience problems downloading a file, check if you have the proper ... the access to
this document is restricted, you may want ... v:3:y:1979:i:4:p:339-338 Keywords: ...

The Brazilian Cerrado Vegetation and Threats to its Biodiversity -
JA RATTER, JF RIBEIRO, S BRIDGEWATER - Annals of Botany, 1997 - Annals Botany Co
... Search Agricola for articles by: RATTER JA || BRIDGEWATER S. ... If you have not installed
and configured the Adobe Acrobat Reader on your system, see Help with ...

The relationship between return and market value of common stocks
RW Banz - Journal of Financial Economics, 1981 - ideas.repec.org
... ReDIF Handle: RePEc:eee:jfinec:v:9:y:1981:i:1:p:3-18 Keywords: ... by uploading them
on the Munich Personal RePEc Archive (MPRA) if you do not have access to an ...

In search of a useful theory of innovation -
RR Nelson, SG Winter - Research Policy, 1977 - ideas.repec.org
... If you experience problems downloading a file, check if you have the proper application ...
As the access to this document is restricted, you may want to ... Keywords: ...

Pulmonary complications of bone marrow transplantation -
AO Soubani, KB Miller, PM Hassoun - Chest - Am Coll Chest Phys
... Search PubMed for articles by: Soubani, AO || Hassoun, PM. ... If you have not installed
and configured the Adobe Acrobat Reader on your system, see Help with ...

[PDF] Encyclopaedia Britannica -
E Britannica? - 1967 - 129.66.12.115
... When you search for a keyword or phrase ... Search results can come from all four
encyclopedias ... Edition receives updates monthly so you have current information ...

Staggered Prices in a Utility-Maximizing Framework
G Calvo - Journal of Monetary Economics, 1983 - ideas.repec.org
... experience problems downloading a file, check if you have the proper ... the access to
this document is restricted, you may want ... 12:y:1983:i:3:p:383-398 Keywords: ...

Management Ownership and Market Valuation: An Empirical Analysis
R Morck, A Shleifer, R Vishny - Journal of Financial Economics, 1988 - ideas.repec.org
... experience problems downloading a file, check if you have the proper ... the access to
this document is restricted, you may want ... v:20:y:1988:i::p:293-315 Keywords: ...

Source: Google Scholar

Iloperidone Phase III Clinical Data Demonstrate Efficacy And Favorable Safety And Tolerability Profile

 
Titan Pharmaceuticals, Inc. (AMEX: TTP) announced that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile.

These results were included as part of the recently filed New Drug Application (NDA) for iloperidone and were presented by Titan's corporate partner, Vanda Pharmaceuticals, Inc., for the first time this week at a major psychiatric congress. The U.S. Food and Drug Administration (FDA) accepted the NDA submitted by Vanda for marketing approval on November 26, 2007.

The final Phase III study conducted by Vanda evaluated the efficacy of iloperidone versus placebo in patients with schizophrenia. The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24 mg/day, ziprasidone at 160 mg/day, or placebo. Patients treated with iloperidone had significantly greater improvements in Positive and Negative Syndrome Scale-Total (PANSS-T) scores than those on placebo and had PANSS-T improvement comparable to ziprasidone.
Iloperidone and ziprasidone showed similarly low effects on glucose, cholesterol, triglyceride and prolactin levels compared to placebo, and iloperidone was also associated with a favorable profile on the Extrapyramidal Symptoms Rating Scale (ESRS) versus placebo.

Additionally, iloperidone also had a similar akathisia profile to placebo, whereas ziprasidone was associated with a significant worsening of akathisia versus placebo on the Barnes Akathisia Scale (BAS), with 26 percent of patients experiencing a worsening of akathisia. Akathisia is a debilitating sensation of restlessness that can be unrelenting with symptoms that may occur around the clock.

A post-hoc, pooled analysis of three additional Phase III trials was also presented this week. Each trial was a randomized, double-blind, placebo- and active-controlled, parallel-group, six-week trial of patients with schizophrenia or schizoaffective disorder. The analysis evaluated change from baseline using the Brief Psychiatric Rating Scale (BPRS) for the 1,553 patients who remained on treatment for more than two weeks. Iloperidone demonstrated generally significant improvements over placebo in doses ranging from 4-8 mg/day to 20-24 mg/day; similar reductions in BPRS scores were observed at six weeks for iloperidone in doses of 20-24 mg/day, as compared to the active comparators risperidone and haloperidol. The analysis further demonstrated that iloperidone had a favorable safety profile, most notably with regard to extrapyramidal symptoms (EPS) and akathisia rates, weight and metabolic parameters, and prolactin levels.

Unmet Needs in Schizophrenia

Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately one percent of Americans. Although there are many drugs approved to treat schizophrenia, including the commonly prescribed "atypical antipsychotics," a high degree of dissatisfaction remains among physicians and patients. The recent CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) study, conducted by the National Institute of Mental Health (NIMH) and reported in The New England Journal of Medicine, evaluated several antipsychotic medications and revealed that 74 percent of patients taking antipsychotics discontinued treatment within 18 months, primarily because of insufficient efficacy and tolerability issues.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (AMEX: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders. Titan's products in development utilize novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes partnerships with government institutions and other leading pharmaceutical development companies.

http://www.titanpharm.com

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

Titan Pharmaceuticals
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.